145 related articles for article (PubMed ID: 36868052)
1. Cell-free DNA methylation biomarker for the diagnosis of papillary thyroid carcinoma.
Hong S; Lin B; Xu M; Zhang Q; Huo Z; Su M; Ma C; Liang J; Yu S; He Q; Su Z; Li Y; Liu R; Guo Z; Lv W; Xiao H
EBioMedicine; 2023 Apr; 90():104497. PubMed ID: 36868052
[TBL] [Abstract][Full Text] [Related]
2.
Li J; Yin Y; Huang H; Li M; Li H; Zhang M; Jiang C; Yang R
Epigenomics; 2023 Dec; 15(23):1257-1272. PubMed ID: 38126720
[No Abstract] [Full Text] [Related]
3. Integrative metabolomic characterization identifies plasma metabolomic signature in the diagnosis of papillary thyroid cancer.
Yu S; Liu C; Hou Y; Li J; Guo Z; Chen X; Zhang L; Peng S; Hong S; Xu L; Li X; Liu R; Chen S; Li B; Weng Z; Li Y; Lv W; Yu J; Xiao H
Oncogene; 2022 Apr; 41(17):2422-2430. PubMed ID: 35279704
[TBL] [Abstract][Full Text] [Related]
4. Altered expression of DLG1-AS1 distinguished papillary thyroid carcinoma from benign thyroid nodules.
He T; Wang H; Sun J; Wu J; Gong F; Li S; Wang H; Li Y
BMC Endocr Disord; 2019 Nov; 19(1):122. PubMed ID: 31718630
[TBL] [Abstract][Full Text] [Related]
5. Serum-plasma matched metabolomics for comprehensive characterization of benign thyroid nodule and papillary thyroid carcinoma.
Huang FQ; Li J; Jiang L; Wang FX; Alolga RN; Wang MJ; Min WJ; Ma G; Zhao YJ; Wang SL; Yu Y; Chen X; Zhu D; Zhu J; Wang G; Xia T; Sang JF; Lai MD; Li P; Zhu W; Qi LW
Int J Cancer; 2019 Feb; 144(4):868-876. PubMed ID: 30318614
[TBL] [Abstract][Full Text] [Related]
6. DNA Methylation-Based Method to Differentiate Malignant from Benign Thyroid Lesions.
Barros-Filho MC; Dos Reis MB; Beltrami CM; de Mello JBH; Marchi FA; Kuasne H; Drigo SA; de Andrade VP; Saieg MA; Pinto CAL; Kowalski LP; Rogatto SR
Thyroid; 2019 Sep; 29(9):1244-1254. PubMed ID: 31328658
[No Abstract] [Full Text] [Related]
7. Hypermethylated RASSF1 and SLC5A8 promoters alongside BRAF
Khatami F; Larijani B; Heshmat R; Nasiri S; Haddadi-Aghdam M; Teimoori-Toolabi L; Tavangar SM
J Cell Physiol; 2020 Oct; 235(10):6954-6968. PubMed ID: 32017063
[TBL] [Abstract][Full Text] [Related]
8. A diagnostic model based on DNA methylation haplotype block characteristics for identifying papillary thyroid carcinoma from thyroid adenoma.
Xu D; Lai Y; Liu H; Li H; Feng N; Liu Y; Gong C; Zhang Y; Zhou J; Shen Y
Transl Res; 2024 Feb; 264():76-84. PubMed ID: 37863284
[TBL] [Abstract][Full Text] [Related]
9. Exosomal miRNAs are potential diagnostic biomarkers between malignant and benign thyroid nodules based on next-generation sequencing.
Pan Q; Zhao J; Li M; Liu X; Xu Y; Li W; Wu S; Su Z
Carcinogenesis; 2020 Mar; 41(1):18-24. PubMed ID: 31560760
[TBL] [Abstract][Full Text] [Related]
10. Role of differentially expressed genes and long non-coding RNAs in papillary thyroid carcinoma diagnosis, progression, and prognosis.
Cai WY; Chen X; Chen LP; Li Q; Du XJ; Zhou YY
J Cell Biochem; 2018 Nov; 119(10):8249-8259. PubMed ID: 29968931
[TBL] [Abstract][Full Text] [Related]
11. TROP-2 expression in papillary thyroid carcinoma: Potential Diagnostic Utility.
Simms A; Jacob RP; Cohen C; Siddiqui MT
Diagn Cytopathol; 2016 Jan; 44(1):26-31. PubMed ID: 26481593
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive DNA Methylation Profiling Identifies Novel Diagnostic Biomarkers for Thyroid Cancer.
Park JL; Jeon S; Seo EH; Bae DH; Jeong YM; Kim Y; Bae JS; Kim SK; Jung CK; Kim YS
Thyroid; 2020 Feb; 30(2):192-203. PubMed ID: 31797753
[No Abstract] [Full Text] [Related]
13. High BRAFV600E mutation frequency in Chinese patients with papillary thyroid carcinoma increases diagnostic efficacy in cytologically indeterminate thyroid nodules.
Li XJ; Mao XD; Chen GF; Wang QF; Chu XQ; Hu X; Ding WB; Zeng Z; Wang JH; Xu SH; Liu C
Medicine (Baltimore); 2019 Jul; 98(28):e16343. PubMed ID: 31305422
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.
Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X
Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867
[TBL] [Abstract][Full Text] [Related]
15. DNA Methylation Status of HYAL1 in Malignant and Benign Thyroid Nodules.
Li M; Yin Y; Zhang M; Jiang C; Li H; Yang R
Horm Metab Res; 2023 Dec; 55(12):869-875. PubMed ID: 38040022
[TBL] [Abstract][Full Text] [Related]
16. Methylation markers differentiate thyroid cancer from benign nodules.
Stephen JK; Chen KM; Merritt J; Chitale D; Divine G; Worsham MJ
J Endocrinol Invest; 2018 Feb; 41(2):163-170. PubMed ID: 28612287
[TBL] [Abstract][Full Text] [Related]
17. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.
Iancu IV; Botezatu A; Plesa A; Huica I; Fudulu A; Albulescu A; Bostan M; Mihaila M; Grancea C; Manda DA; Dobrescu R; Vladoiu SV; Anton G; Badiu CV
Cancer Biomark; 2020; 28(2):255-268. PubMed ID: 32390600
[TBL] [Abstract][Full Text] [Related]
18. Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: improvement in the sensitivity or specificity?
Wu G; Wang J; Zhou Z; Li T; Tang F
J Int Med Res; 2013 Aug; 41(4):975-83. PubMed ID: 23857157
[TBL] [Abstract][Full Text] [Related]
19. [Detection of DNA methylation of
Yin Y; Li H; Yang C; Zhang M; Huang X; Li M; Yang R; Zhang Z
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Jan; 42(1):123-129. PubMed ID: 35249879
[TBL] [Abstract][Full Text] [Related]
20. Significance of BRAF V600E Mutation and Cytomorphological Features for the Optimization of Papillary Thyroid Cancer Diagnostics in Cytologically Indeterminate Thyroid Nodules.
Beiša A; Kvietkauskas M; Beiša V; Stoškus M; Ostanevičiūtė E; Jasiūnas E; Griškevičius L; Šeinin D; Šileikytė A; Strupas K
Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):247-254. PubMed ID: 29566402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
